Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ICAD | Director Stock Option (right to buy) | Disposed to Issuer | -90K | -100% | 0 | Nov 16, 2018 | Common Stock | 90K | $2.89 | Direct | F1, F2 | ||
transaction | ICAD | Director Stock Option (right to buy) | Award | +90K | 90K | Mar 7, 2023 | Common Stock | 90K | $2.89 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years.? No other modification was made to the option. |
F2 | The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 16, 2018 and is fully vested as of the date hereof. |